Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics

Schizophrenia Research

Volumn 125, Issue 2-3, 2011, Pages 179-186

  Bai, Ya Mei ^a,b   Chen, Tzu Ting ^c   Liou, Ying Jay ^a,b   Hong, Chen Jee ^a,b   Tsai, Shih Jen ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

Author keywords

Antipsychotic; HTR2C; Metabolic syndrome; Single nucleotide polymorphisms

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; RISPERIDONE; SEROTONIN 2C RECEPTOR;

ADULT; ALLELE; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION GENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HOMOZYGOTE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SEX FACTORS;

EID: 78951473163     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.11.030     Document Type: Article

References (30)

1. Bonhaus D.W., Weinhardt K.K., Taylor M., DeSouza A., McNeeley P.M., Szczepanski K., Fontana D.J., Trinh J., Rocha C.L., Dawson M.W., Flippin L.A., Eglen R.M. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology 1997, 36:621-629.
2. Bymaster F.P., Nelson D.L., DeLapp N.W., Falcone J.F., Eckols K., Truex L.L., Foreman M.M., Lucaites V.L., Calligaro D.O. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr. Res. 1999, 37:107-122.
3. Correll C.U., Frederickson A.M., Kane J.M., Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome. Schizophr. Res. 2007, 89:91-100.
4. De Hert M., Schreurs V., Sweers K., Van Eyck D., Hanssens L., Sinko S., Wampers M., Scheen A., Peuskens J., van Winkel R. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr. Res. 2008, 101:295-303.
5. De Hert M., Schreurs V., Vancampfort D., Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009, 8:15-22.
6. De Hert M.A., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 2006, 83:87-93.
7. Di Matteo V., Cacchio M., Di Giulio C., Di Giovanni G., Esposito E. Biochemical evidence that the atypical antipsychotic drugs clozapine and risperidone block 5-HT(2C) receptors in vivo. Pharmacol. Biochem. Behav. 2002, 71:607-613.
8. Dehning S., Müller N., Matz J., Bender A., Kerle I., Benninghoff J., Musil R., Spellmann I., Bondy B., Möller H.J., Riedel M., Zill P. A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. Psychiatr. Genet. 2010, 20:35-38.
9. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum. Hered. 2008, 66:87-98.
10. Gundlah C., Pecins-Thompson M., Schutzer W.E., Bethea C.L. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res. Mol. Brain Res. 1999, 63:325-339.
11. Henderson J.A., Bethea C.L. Differential effects of ovarian steroids and raloxifene on serotonin 1A and 2C receptor protein expression in macaques. Endocr. 2008, 33:285-293.
12. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Williams G.C., Tu X., Tang W., Wiener K., Dvorin S., Dietz M.B. Prevalence of the metabolic syndrome among patients receiving clozapine. Am. J. Psychiatry 2006, 163:1273-1276.
13. Liou, Y.J., Bai, Y.M., Lin, E., Chen, J.Y., Che, Z.T., Hong, C.J., Tsai, S.J., (in press). Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J.
14. Liu B.C., Zhang J., Wang L., Li X.W., Wang Y., Wei Z.Y., Ji J., Yang F.P., Wan C.L., Xu Y.F., Feng G.Y., He L., He G. HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients. Pharmacogenomics 2010, 11:685-692.
15. Mannucci E., Monami M., Cresci B., Pala L., Bardini G., Petracca M.G., Dicembrini I., Pasqua A., Buiatti E., Rotella C.M. National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study. Diabetes Obes. Metab. 2008, 10:430-435.
16. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80:19-32.
17. Medved V., Kuzman M.R., Jovanovic N., Grubisin J., Kuzman T. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. J. Psychopharmacol. 2009, 23:915-922.
18. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand. 2009, 119:4-14.
19. Mulder H., Cohen D., Scheffer H., Gispen-de Wied C., Arends J., Wilmink F.W., Franke B., Egberts A.C. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J. Clin. Psychopharmacol. 2009, 29:16-20.
20. Mulder H., Franke B., van der-Beek van der, A.A., Arends J., Wilmink F.W., Scheffer H., Egberts A.C. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J. Clin. Psychopharmacol. 2007, 27:338-343.
21. Reynolds G.P., Zhang Z., Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am. J. Psychiatry 2003, 160:677-679.
22. Reynolds G.P., Zhang Z.J., Zhang X.B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002, 359:2086-2087.
23. Risselada, A.J., Vehof, J., Bruggeman, R., Wilffert, B., Cohen, D., Al Hadithy, A.F., Arends, J., Mulder, H., (in press). Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study. Pharmacogenomics J.
24. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr. Res. 2008, 101:266-272.
25. Smith S.R., Weissman N.J., Anderson C.M., Sanchez M., Chuang E., Stubbe S., Bays H., Shanahan W.R. Multicenter, placebo-controlled trial of lorcaserin for weight management. N. Engl. J. Med. 2010, 363:245-256. Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group.
26. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995, 374:542-546.
27. Tsai S.J., Hong C.J., Yu Y.W., Lin C.H. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002, 360:1790.
28. Videtic A., Peternelj T.T., Zupanc T., Balazic J., Komel R. Promoter and functional polymorphisms of HTR2C and suicide victims. Genes Brain Behav. 2009, 8:541-545.
29. Yevtushenko O.O., Cooper S.J., O'Neill R., Doherty J.K., Woodside J.V., Reynolds G.P. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br. J. Psychiatry 2008, 192:424-428.
30. Zhou L., Sutton G.M., Rochford J.J., Semple R.K., Lam D.D., Oksanen L.J., Thornton-Jones Z.D., Clifton P.G., Yueh C.Y., Evans M.L., McCrimmon R.J., Elmquist J.K., Butler A.A., Heisler L.K. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007, 6:398-405.